Mustang Bio, Inc. (NASDAQ:MBIO) Short Interest Update

Mustang Bio, Inc. (NASDAQ:MBIO) was the target of a large growth in short interest during the month of March. As of March 31st, there was short interest totaling 125,433 shares, a growth of 48.1% from the March 15th total of 84,718 shares. Approximately 1.7% of the company’s shares are short sold. Based on an average daily volume of 37,937 shares, the short-interest ratio is presently 3.3 days.

Wall Street Analyst Weigh In

Separately, Weiss Ratings restated a “sell (e+)” rating on shares of Mustang Bio in a report on Thursday, January 22nd. One equities research analyst has rated the stock with a Sell rating, According to MarketBeat, Mustang Bio presently has a consensus rating of “Sell”.

Mustang Bio Stock Performance

Shares of Mustang Bio stock traded down $0.01 during midday trading on Thursday, reaching $0.76. 16,123 shares of the company’s stock traded hands, compared to its average volume of 151,183. The company has a market cap of $5.72 million, a PE ratio of -1.94 and a beta of 2.18. The stock has a 50 day moving average of $0.86 and a 200-day moving average of $1.11. Mustang Bio has a 12 month low of $0.53 and a 12 month high of $7.00.

Mustang Bio (NASDAQ:MBIO) last announced its earnings results on Thursday, March 19th. The company reported ($0.07) EPS for the quarter. On average, equities analysts anticipate that Mustang Bio will post -35 earnings per share for the current fiscal year.

Hedge Funds Weigh In On Mustang Bio

An institutional investor recently raised its position in Mustang Bio stock. Kestra Advisory Services LLC lifted its holdings in Mustang Bio, Inc. (NASDAQ:MBIO) by 68.0% in the 4th quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund owned 111,042 shares of the company’s stock after purchasing an additional 44,934 shares during the quarter. Kestra Advisory Services LLC owned 1.52% of Mustang Bio worth $109,000 as of its most recent filing with the Securities and Exchange Commission (SEC). 9.95% of the stock is currently owned by institutional investors.

Mustang Bio Company Profile

Mustang Bio, Inc is a clinical‐stage biopharmaceutical company focused on the development and commercialization of novel cell and gene therapies for oncology and rare genetic diseases. The company’s primary platform leverages chimeric antigen receptor T‐cell (CAR-T) technology to target both hematologic and solid tumor indications. In parallel, Mustang Bio is advancing a portfolio of lentiviral‐based gene therapy candidates designed to address inherited metabolic disorders with high unmet medical need.

The company’s oncology pipeline includes programs directed at B-cell malignancies and aggressive brain tumors, with lead CAR-T candidates in clinical trials for glioblastoma multiforme and various B-cell leukemias and lymphomas.